AdvanCell Enters Into Strategic Collaboration with Lilly to Advance Novel Targeted Alpha Therapies for the Treatment of Cancer

Contributed by: Business Wire

Logo

Tags

Radiology

Other Science

Pharmaceutical

Research

Oncology

Infectious Diseases

Hospitals

Genetics

Stem Cells

Science

Practice Management

Physical Therapy

Clinical Trials

General Health

Biotechnology

Surgery

Health

Health Technology

Eli Lilly

More Like This

AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing

AdvanCell to participate in Jefferies Global Healthcare Conference in London

AdvanCell to Present Promising Clinical Trial Results of ADVC001, a Novel Lead-212-based PSMA-targeted Alpha Therapy for Prostate Cancer, at ESMO 2025

AdvanCell Proudly Announces $18M in Federal Funding from the Medical Research Future Fund (MRFF) Frontiers Initiative for ‘Defeating Prostate Cancer with Targeted Alpha Therapy’

AdvanCell’s 212Pb-ADVC001 demonstrates encouraging safety and compelling anti-tumor activity in Phase 1b in prostate cancer

AdvanCell Appoints Philina Lee, PhD as Chief Executive Officer to Lead US Expansion and Drive Global Growth

PR Newswire associated0

IONETIX Corporation and AlfaRim Medical B.V. announce a strategic partnership to fast-track commercial production of Actinium-225

PR Newswire associated0

ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals to Advance a First-in-Class Alpha Radioligand Therapy for Solid Tumors